Biodexa Pharmaceuticals Plc (BDRX)

Market Cap	3.62M
Revenue (ttm)	104,895
Net Income (ttm)	-8.62M
Shares Out	580.84K
EPS (ttm)	-45.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,729
Open	5.85
Previous Close	5.98
Day's Range	5.77 - 6.43
52-Week Range	4.71 - 220.25
Beta	1.43
Analysts	Strong Buy
Price Target	200.00 (+3,105.13%)
Earnings Date	Oct 29, 2024

About BDRX

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: BDRX
• Website: https://www.biodexapharma.com

Financial Performance

In 2023, Biodexa Pharmaceuticals's revenue was 381,000, a decrease of -45.49% compared to the previous year's 699,000. Losses were -7.08 million, -7.54% less than in 2022.

Financial numbers in GBP

Analyst Forecast

According to one analyst, the rating for BDRX stock is "Strong Buy" and the 12-month stock price forecast is $200.0.

Price Target

$200.0

(3,105.13% upside)

Analyst Consensus: Strong Buy